ESG in pharmaceutical quality assurance requires careful judgement about where quality responsibilities meet wider business expectations. Environmental, social and governance considerations can affect supplier selection, operational improvements and the evidence requested by customers. QA teams have useful skills to contribute, but their role needs to be defined alongside sustainability, procurement, engineering and legal colleagues.
In 2026, these expectations need to be understood alongside a changing regulatory picture. EU reporting obligations have been narrowed, so it would be inaccurate to suggest that every pharmaceutical business faces expanding legal duties. The stronger argument for QA involvement concerns reliable evidence and responsible operational decisions, including where expectations arise through supplier relationships.
Understand the changing regulatory position
In February 2026, the Council of the EU gave final approval to changes narrowing the Corporate Sustainability Reporting Directive’s scope to companies with more than 1,000 employees and net annual turnover above €450 million. The package also narrowed sustainability due diligence obligations and changed their timetable.
Applicability should therefore be checked for the relevant entity, group and jurisdiction, including national implementation and transitional provisions. QA should work with the functions responsible for interpreting these obligations. A site’s quality team should not assume that a customer questionnaire establishes a legal reporting duty or that a regulatory exemption removes every contractual request.
As a practical step, distinguish statutory obligations from contractual commitments and voluntary goals. Record who owns each requirement and which evidence supports it. This makes it easier to respond consistently when different customers ask similar questions using different terminology.
Responsible sourcing reaches beyond a quality certificate
The Pharmaceutical Supply Chain Initiative provides a primary industry framework for responsible supplier practices. Its principles cover areas including human rights, health and safety, environmental responsibility, ethics and governance. Member companies are expected to incorporate the principles into key supplier documents and agreements.
This demonstrates a route through which broader expectations can reach pharmaceutical suppliers. For QA, the practical task is to identify where existing qualification activities intersect with these requests and where another function needs to lead. A satisfactory GMP assessment, for example, should not be treated as proof that a supplier has met an unrelated environmental commitment.
A coordinated supplier review can prevent duplication. Procurement can clarify the commercial requirement, sustainability specialists can define the requested information and QA can contribute relevant quality risk and documentation expertise. Escalation arrangements should explain how a concern affecting both supply continuity and responsible sourcing is considered.
Apply evidence discipline to sustainability information
A sustainability figure is more useful when its source and calculation are clear. Consider a hypothetical claim that a site has reduced water consumption. Reviewers need to know the measurement period, the site boundary and whether production activity changed. A reduction in total consumption may have a different meaning from a reduction per batch.
QA teams can recommend familiar controls such as named data owners, approved calculation methods and recorded corrections. These are proposed governance practices; ESG information should not automatically be classified as GMP data. The appropriate control depends on how the information is used and the obligations attached to it.
Where a business publishes a claim, the relevant owners should check that it matches the evidence. Narrow, measurable wording is easier to defend than a broad statement that a process is sustainable. An unresolved estimate should remain identifiable as an estimate when information moves from a site spreadsheet to a corporate report.
Evaluate environmental improvements through quality change control
Sustainability projects may propose changes to cleaning, packaging or utility operation. Where those changes affect a GMP process, established quality change control applies. ICH Q10 describes evaluation of proposed changes using quality risk management and assessment after implementation.
For example, a proposal to shorten a cleaning cycle should specify the expected environmental benefit and the evidence needed to show that cleaning remains suitable. Bringing QA into the proposal early allows the team to agree on the study requirements before a target or deadline becomes fixed.
Environmental risks can also have a direct public health dimension. WHO’s 2024 guidance addresses wastewater and solid waste from antibiotic manufacturing, including measures intended to limit pollution that contributes to antimicrobial resistance. It is a specific example, not a universal ESG rule for all pharmaceutical products. Sites involved in these supply chains should understand the relevance to their operations.
Build a proportionate QA contribution
ESG in pharmaceutical quality assurance is most useful when responsibilities are clear, and information can be substantiated. Begin by mapping the requests reaching your site, then identify the decisions requiring quality input. This creates a manageable programme while protecting attention for product quality and patient safety.
QA Resources provides quality systems, vendor assurance and quality risk management support. Contact the team to discuss strengthening the quality processes that intersect with responsible sourcing and sustainability projects, while retaining appropriate ownership with your ESG and legal specialists.